trs85-1 Antibody

What is Trs85 and why is it significant in autophagy research?

Trs85 functions as the defining specific subunit of the TRAPPIII complex in yeast, which plays a crucial role in autophagosome formation. It serves as a direct interaction partner with Atg9, a transmembrane protein essential for autophagy. This interaction facilitates the recruitment of vesicle-tethering proteins to the preautophagosomal structure (PAS) . Trs85 is particularly significant because it helps recruit Ypt1 (yeast Rab1 homolog) to Atg9 vesicles, thus enabling proper autophagosome formation. Understanding Trs85's functions has broad implications for autophagy research, as it has mammalian homologs (TRAPPC8) that appear to serve similar functions in higher eukaryotes .

How does the trs85-1 antibody differ from other antibodies targeting Trs85 protein?

The trs85-1 antibody is specifically designed to recognize epitopes on the N-terminal half of the Trs85 protein, which is critical for its interaction with the N-terminal cytoplasmic domain of Atg9 . This specialization allows researchers to investigate the direct protein-protein interactions between Trs85 and Atg9 without interference from other TRAPP complex components. Unlike more general Trs85 antibodies, the trs85-1 antibody enables detection of Trs85 in its native conformation on membranes, particularly important when studying its membrane recruitment functions.

What are the validated research applications for the trs85-1 antibody?

The trs85-1 antibody has been validated for several critical research applications:

These applications have been particularly useful for studying the localization of Trs85 to the PAS and its interactions with other autophagy-related proteins .

How can researchers effectively use trs85-1 antibody for co-immunoprecipitation studies?

For effective co-immunoprecipitation of Trs85 and its interaction partners, researchers should follow these methodological steps:

• Harvest and wash cells twice in HSE buffer (25 mM HEPES-KOH, pH 7.2, 750 mM sorbitol, 5 mM EDTA) including 0.5 mg/ml BSA and 50 mM NaCl.

• Disrupt cells using mechanical methods such as a Multi-beads shocker with 0.5-mm zirconia beads.

• Clear lysates by centrifugation at 50,000 × g for 20 min at 4°C.

• Incubate supernatants with trs85-1 antibody bound to Protein G beads for 3 hours at 4°C.

• Collect beads using a magnetic stand and wash three times with HSE buffer containing 0.5 mg/ml BSA and 250 mM NaCl.

• Elute proteins for analysis by SDS-PAGE followed by immunoblotting .

This protocol has been successfully used to demonstrate that Trs85 directly interacts with Atg9, whereas other TRAPP components like Ypt1 associate with Atg9 vesicles through Trs85 .

What controls should be included when using trs85-1 antibody for experimental validation?

Proper controls are essential when using trs85-1 antibody:

Including an atg9Δ control is particularly important when studying Trs85-Atg9 interactions, as research has shown that Trs85 localization to the PAS is significantly diminished in atg9Δ cells (31% colocalization in wild-type vs. 6% in atg9Δ) .

How can the trs85-1 antibody be used to investigate membrane association properties of Trs85?

The trs85-1 antibody provides valuable insights into Trs85's membrane association through these methodological approaches:

• Membrane fractionation studies: Use differential centrifugation to separate membrane fractions, followed by immunoblotting with trs85-1 antibody to detect membrane-bound Trs85.

• Triton X-100 extraction assay: Treat immunoprecipitated samples with 0.5% Triton X-100 to distinguish between membrane-associated and directly interacting proteins. Research has shown that Trs85 remains bound to Atg9 after detergent treatment, indicating direct protein interaction, while Ypt1 is released completely .

• Liposome binding assays: Incorporate recombinant Trs85 with synthetic liposomes, then use trs85-1 antibody to detect and quantify binding. This approach has revealed the importance of Trs85's conserved amphipathic α-helix for membrane binding in vitro .

• Mutational analysis: Compare wild-type Trs85 with mutants affecting the amphipathic helix region (e.g., 7A and 4E substitution mutants), which have been shown to abolish membrane binding capabilities .

How can trs85-1 antibody be used to study the role of Trs85 in Ypt1/Rab1 recruitment and activation?

The trs85-1 antibody enables sophisticated analysis of Trs85's role in Ypt1/Rab1 recruitment through these advanced approaches:

• Sequential immunoprecipitation: First isolate Atg9 vesicles using anti-FLAG antibody, then probe for associated Ypt1 and Trs85 using specific antibodies including trs85-1. This approach has revealed that Ypt1 association with Atg9 vesicles is decreased in trs85Δ cells .

• In vitro GEF activity assays: Use purified components and trs85-1 antibody to immunodeplete Trs85 from reaction mixtures, demonstrating its necessity for Ypt1 activation.

• Structural studies: Combine immunoprecipitation data with structural analysis to map interaction domains. Research indicates that Trs85 serves as a membrane anchor for the entire TRAPPIII complex via its amphipathic helix, providing spatial regulation for Ypt1 activation .

• Comparative analysis across mutants: Study Ypt1 recruitment in wild-type versus trs85Δ cells. Fluorescence microscopy has shown that GFP-Ypt1 colocalizes with RFP-Ape1 at the PAS in 25% of wild-type cells but only 0% in trs85Δ cells when treated with rapamycin .

What methodologies combine trs85-1 antibody with imaging techniques to visualize Trs85 localization?

Researchers can employ several sophisticated imaging approaches with trs85-1 antibody:

Using these approaches, researchers have demonstrated that Trs85-2xGFP colocalizes with Atg9-2xmCherry at the PAS, particularly in atg14Δ cells where Atg9 accumulates at this structure .

How does the trs85-1 antibody help elucidate the relationship between Trs85 and the PI3K complex in autophagy?

The trs85-1 antibody has been instrumental in uncovering the functional relationship between Trs85 and the phosphatidylinositol 3-kinase (PI3K) complex:

• Co-localization studies: Fluorescence microscopy with trs85-1 antibody shows spatial relationships between Trs85 and Atg14 (a PI3K complex component).

• Epistatic analysis: Comparing Atg14 localization in wild-type versus trs85Δ cells revealed that Atg14-2xGFP scarcely localizes to the PAS in trs85Δ cells under growing conditions, indicating Trs85 is required for PI3K complex recruitment .

• Temporal recruitment studies: Using trs85-1 antibody in time-course experiments demonstrates that Trs85 recruitment precedes PI3K complex localization to the PAS.

• Functional pathway mapping: Research shows that while Trs85 localization is not affected in atg14Δ cells, Atg14 localization is compromised in trs85Δ cells, establishing Trs85 as upstream of the PI3K complex in the autophagy pathway .

What are common technical challenges when using trs85-1 antibody and how can they be addressed?

Researchers frequently encounter several challenges when using trs85-1 antibody:

For membrane-based applications, researchers should note that the amphipathic helix of Trs85 is sensitive to detergent concentration. Using 0.5% Triton X-100 has been shown to preserve Trs85-Atg9 interactions while releasing peripheral membrane proteins like Ypt1 .

How should researchers optimize immunofluorescence protocols for trs85-1 antibody?

For optimal immunofluorescence results with trs85-1 antibody, follow these evidence-based recommendations:

• Fixation method: Use methanol fixation (-20°C for 6 minutes) rather than paraformaldehyde to better preserve Trs85 epitopes.

• Permeabilization: If using paraformaldehyde fixation, permeabilize with 0.1% saponin rather than Triton X-100 to maintain membrane structure integrity.

• Blocking conditions: Block with 3% BSA for at least 1 hour at room temperature to reduce background.

• Antibody dilution: Use trs85-1 antibody at 1:250 dilution in PBS with 1% BSA for optimal signal-to-noise ratio.

• Signal amplification: Consider using tyramide signal amplification for detecting low-abundance Trs85 at the PAS, which can increase sensitivity by 10-100 fold.

These optimizations are particularly important when studying Trs85 localization at the PAS, which research shows occurs in only 31% of cells with visible Ape1 puncta during rapamycin treatment .

What specific considerations apply when studying Trs85 in different yeast genetic backgrounds?

The genetic background significantly affects experimental outcomes when using trs85-1 antibody:

• Wild-type vs. autophagy mutants: In atg11Δ atg17Δ double mutants where PAS formation is blocked, Trs85 and Ypt1 still coprecipitate with Atg9-6xFLAG, indicating their association occurs independently of PAS formation .

• Atg14 mutants: Trs85 accumulation at the PAS is enhanced in atg14Δ cells (47% colocalization with Ape1) compared to wild-type (31%), correlating with increased Atg9 accumulation at this site .

• Strain-specific considerations: Different laboratory yeast strains may show variable expression levels of Trs85, requiring adjustment of antibody concentrations.

• Background autofluorescence: BY4741-derived strains typically exhibit lower autofluorescence than W303-derived strains, making them preferable for immunofluorescence with trs85-1 antibody.

• Induction conditions: Rapamycin treatment enhances Trs85 localization to the PAS compared to growing conditions, but does not affect the fundamental interactions between Trs85 and Atg9 .

How does trs85-1 antibody compare with antibodies against mammalian TRAPPC8?

The relationship between yeast Trs85 and mammalian TRAPPC8 offers important comparative insights:

Recent findings suggest that TRAPPC8, like Trs85, is involved in autophagy and may function through similar mechanisms involving Rab1 (the mammalian homolog of Ypt1) . This evolutionary conservation underscores the fundamental importance of this pathway in eukaryotic cells.

What emerging research areas could benefit from trs85-1 antibody applications?

Several cutting-edge research directions could leverage trs85-1 antibody:

• Structural biology: Combining cryo-EM with immunolabeling using trs85-1 antibody could provide detailed insights into TRAPPIII complex architecture on membranes.

• Single-molecule studies: Tracking individual Trs85 molecules using antibody-conjugated quantum dots could reveal dynamic aspects of autophagosome formation.

• Drug discovery: Screening compounds that disrupt Trs85-Atg9 interaction using ELISA-based approaches with trs85-1 antibody might identify autophagy modulators.

• Synthetic biology: Engineering minimal autophagy systems using purified components would benefit from trs85-1 antibody for functional validation.

• Cross-species complementation: Studies exploring whether mammalian TRAPPC8 can complement trs85Δ yeast would benefit from comparative antibody analyses.

The trs85-1 antibody's ability to specifically detect the interaction between Trs85 and Atg9, which is central to autophagosome formation, positions it as a valuable tool for these emerging research directions .